Drug intelligence / Profile preview

Huli San Tablets

Development stage: Unknown
Lead developer: Nanchang Hongyi Pharmaceutical
Administration: Oral

Overview

Huli San Tablets (虎力散片) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Nanchang Hongyi Pharmaceutical. It is an approved pharmaceutical product in China, primarily indicated for the treatment of traumatic injuries, bone fractures, and inflammatory conditions such as rheumatoid arthritis. The formulation is designed to promote blood circulation, resolve blood stasis, and provide analgesic effects. It typically contains a combination of herbal ingredients, including *Panax notoginseng* (Sanqi), *Paris polyphylla* (Chonglou), and *Aconitum brachypodum* (Xueshangyizhihao), which contribute to its anti-inflammatory and pain-relieving properties.

Brand names: 虎力散片
Other names: Huli San TabletsHulisan TabletsHulisan Pian

Beyond the preview

Go deeper on Huli San Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huli San Tablets.

Explore the full profile